摘要
目的：比较头孢哌酮-舒巴坦2：1配方与1：1配方治疗医院获得性肺炎的临床疗效。方法：选取医院60例获得性肺炎患者随机分为试验组和对照组,各30例,分别静脉滴注头孢哌酮-舒巴坦（2：1为试验组）3.0g或头孢哌酮-舒巴坦（1：1为对照组）3.0g,均q8h,共7~14d,两组均不得联合使用其他抗生素。结果：试验组有效率为96.67%,其中细菌清除率为93.3%;对照组有效率为76.67%,其中细菌清除率76.67%,试验组和对照组对比,均P〈0.05。不良反应发生率分别为10%和6.7%。结论：头孢哌酮-舒巴坦2：1与头孢哌酮-舒巴坦1：1治疗医院获得性肺炎临床疗效有显著差异,头孢哌酮-舒巴坦2：1疗效相对优于头孢哌酮-舒巴坦1：1（P〈0.05）。
Objective：To study the clinical efficacy of two ratios of cefoperazone-sulbactam（1 ： 1 and 2 ： 1）in treatment of hospital-acquired pneumonia. Methods.. Sixty patients with hospital-acquired pneumonia were randomly divided in- to two groups. In the test group, thirty patients were treated with cefoperazone-sulbactam 2：1,3.0g,iv,gtt,qSh for 7 to 14d. The other thirty patients were treated with eefoperazone-sulbactam 1：1,3.0g,iv, gtt, qSh for 7 to 14d in the control group,both groups did not use any other antibiotics. Results：The effective rate of cefoperazone-sulbac- tam 2：1 was 96.67%, and 76.67 % in the control group cefoperazone-sulbactam 1：1（ P 〈0.05）. The bacterial clearance rate was 93.3% in the test group and 76.67% in the control group（ P 〈0.05）. The incidence of adverse reactions of the test group was 10% while that of the control group was 6.7 %. Conclusion：The effectiveness and anti- bacterial effect of the two groups had shown obvious differences in the treatment of hospital-acquired pneumonia（ P 0.05）. For the better clinical efficacy, cefoperazone-sulbactam 2：1 is worthy of promotion in clinical application.
出处
《中外女性健康研究》
2016年第15期17-18,共2页
Women＇s Health Research
